Please ensure Javascript is enabled for purposes of website accessibility

Why Sorrento Therapeutics Stock Jumped Today

By Joe Tenebruso – Jul 1, 2020 at 6:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The COVID-19 antibody-focused company has a promising new coronavirus vaccine candidate.

What happened

Shares of Sorrento Therapeutics (SRNE -4.38%) leapt 10.4% on Wednesday, after the biopharmaceutical company released initial pre-clinical results from its COVID-19 vaccine program. 

So what 

Sorrento said its vaccine candidate T-VIVA-19 (targeted virus vaccine against COVID-19) induced antibodies against SARS-CoV-2, the virus that causes COVID-19, after being injected into mice.

"Approximately 80% of the mice's sera possessed neutralizing antibodies and completely prevented virus infection in in vitro cell cultures using 100 TCID50 viruses and VERO cells," the company said in a press release.

A woman in laboratory safety gear is placing liquids into test tubes with a dropper.

Sorrento Therapeutics' stock rose sharply on Wednesday, after the company released promising early data on its experimental new COVID-19 vaccine. Image source: Getty Images.

Now what

Sorrento intends to seek regulatory authorization to begin clinical trials for T-VIVA-19. At the same time, it will start ramping up its vaccine production and distribution capabilities. 

"If successful and approved, we plan to produce the T-VIVA-19 vaccine in our therapeutic antibody cGMP production facility in San Diego," Sorrento CEO Henry Ji said.

Ji also noted that its experimental vaccine could be easier to produce in large quantities than other COVID-19 vaccine candidates, because of its potentially low dose requirements.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.